Biocartis names chief executive officer
Nayan Gregory Parekh takes up role as current ceo becomes executive chairman
Parekh brings to Biocartis a wealth of pharmaceutical and biotechnology industry experience and has been an executive director of the Board since April 2011.
Rudi Pauwels, co-founder of Biocartis and current ceo, will become executive chairman and = concentrate on the company’s scientific and technology strategy.
Parekh has held senior management positions at Novartis and Deutsche Bank and has a broad network of relationships and experience across a number of healthcare fields and geographies.
Most recently, he was at New Rhein Healthcare, a healthcare investment firm where he was one of the founding partners. Before setting up New Rhein, he spent six years as head of corporate development at Novartis.
Prior to joining Novartis in 2004, Parekh spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors.
You may also like
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Analysis
From ozone protection to climate action: the global transition away from CFCs and HFAs background
In the early 1990s, the world faced a stark environmental warning: the ozone layer, Earth’s natural shield against harmful ultraviolet radiation, was thinning at alarming rates. The culprit? Chlorofluorocarbons (CFCs), chemicals widely used in refrigeration, air conditioning, and even inhalers